Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm study of crovalimab in pediatric atypical hemolytic uremic syndrome
CTR20212792Phase 3Active
- Sponsor
- Roche
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of crovalimab in atypical hemolytic uremic syndrome (aHUS), sponsored by Roche. Started Dec 2023; status: active.
02
Drugs
crovalimab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on CTR20212792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212792.